HCPCS J1325: Injection, epoprostenol 0.5 mg
HCPCS Level II code J1325 describes an injection of epoprostenol, 0.5 mg intended for intravenous infusion therapy to manage pulmonary arterial hypertension; the service is a parenteral prostacyclin therapy typically administered in an inpatient hospital or infusion center/outpatient clinic setting and billed as a drug injection supply for clinician and facility billing workflows.
For related coverage guidance, see recent payer policy updates: Bendamustine Products Coverage Criteria, T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and Romidepsin, Brentuximab Vedotin (Adcetris®) Coverage Criteria.
Customize your policy alerts
Sign up for hcpcs J1325 policy alerts
Get alerted when payer policies referencing J1325 are released or updated.
Monitor payer policy activity